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Objective: The aim of this retrospective longitudinal naturalistic study was to evaluate the 
effects of maintenance lithium treatment on parathyroid hormone (PTH) and calcium levels.
Methods: A retrospective longitudinal naturalistic study design was used. Data were collected 
from the database of a tertiary psychiatric center covering the years 2010–2014. Included were 
bipolar patients who had never been exposed to lithium and had lithium started, and who had 
PTH, and total and ionized calcium levels available before and during lithium treatment. Paired 
t-tests were used to analyze changes in PTH and calcium levels. Linear regressions were per-
formed, with mean lithium level and duration of lithium exposure as independent variables and 
change in PTH levels as dependent variable.
Results: A total 31 patients were included. The mean duration of lithium treatment 
was 18.6±11.4 months. PTH levels significantly increased during lithium treatment 
(+13.55±14.20 pg/mL); the rate of hyperparathyroidism was 12.9%. Neither total nor ionized 
calcium increased from baseline to follow-up; none of our patients developed hypercalcemia. 
Linear regressions analyses did not show an effect of duration of lithium exposure or mean 
lithium level on PTH levels.
Conclusion: Lithium-associated stimulation of parathyroid function is more common than 
assumed to date. Among parameters to be evaluated prior to lithium implementation, calcium 
and PTH should be added.
Keywords: bipolar disorder, follow-up study, lithium side-effects
Introduction
Lithium is recommended by all treatment guidelines for bipolar disorder (BD) as a 
first-line maintenance treatment, and recent trial data have definitely established the 
efficacy of lithium in the prophylaxis of BD.1–10 The clinical benefit of lithium over 
the long term, however, has to be balanced against the risks that it might confer. The 
most commonly reported adverse effects associated with long-term lithium treatment 
are clinical hypothyroidism and reduced urinary concentrating ability.11–13
Less attention has been devoted to alterations in calcium metabolism potentially 
associated with long-term lithium treatment. In case-control studies, lithium treatment 
is associated with increased blood calcium (+0.09 mmol/L) and parathyroid hormone 
(PTH) (+7.32 pg/mL).12 Rates of lithium-associated hyperparathyroidism, however, 
vary enormously between studies, from 2.7% to 23.2% and up to 47.8% in elderly 
patients.14–19 Discrepancies depend on definitions of hyperparathyroidism used and 
different lengths of exposure to lithium in different samples. Rates of subjects with 
hypercalcemia also vary considerably across different studies. When total serum 
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calcium was measured, rates of hypercalcemia were com-
prised between 3.6% (persistent hypercalcemia) and 15.6%; 
when ionized calcium was measured, rates increased to 
25%–42.3%.14,15,20–23 In a recent case-control, cross-sectional 
study, we found that PTH and ionized calcium levels were 
significantly higher in lithium-exposed patients (n=58) 
than in subjects never exposed to lithium (n=54).17 Rates of 
hyperparathyroidism (PTH levels 65 pg/mL) (8.6%) and 
hypercalcemia (ionized calcium 1.32 mmol/L) (24.1%) 
were significantly greater in lithium-exposed subjects.17
The exact prevalence of lithium-associated alterations in 
calcium metabolism and the mechanism by which lithium 
alters serum calcium and PTH levels are to be further deter-
mined. Various hypotheses on the underlying mechanism of 
hyperparathyroidism have been proposed: increased thresh-
old of the calcium-sensing receptor within the parathyroid 
gland; increase of PTH; decrease of the intracellular calcium 
uptake; inhibition of action of glycogen synthase kinase 3b; 
and reduction of PTH gene transcription.24 Prospective longi-
tudinal studies might add useful information on this topic.
To date, only four studies prospectively assessed serum 
calcium and/or PTH levels in patients on long-term lithium 
treatment.25–28 Results of these studies are controversial. 
Aronoff et al evaluated serum calcium levels in 18 patients 
(14 “manic depressive”, mixed unipolar, and bipolar patients, 
and four schizoaffective patients) before lithium, 1 week after 
beginning of lithium and 2 months later, and then off lithium: 
no changes in serum calcium levels were detected.25 Nielsen 
et al found, in ten patients, that PTH increased more than 
40% within the first week on lithium treatment and remained 
elevated throughout the 3-month treatment period.26 No 
significant changes in serum calcium levels were detected. 
Christiansen et al enrolled 13 bipolars that had never been 
treated with any psychopharmacological drugs and followed 
them up for 3 months; serum PTH, calcium, and magnesium 
levels were monthly assessed.27 During lithium treatment, 
serum levels of PTH, calcium, and magnesium significantly 
increased, and this was evident 1 month after institution 
of lithium therapy. Finally, Mak et al studied 53 patients 
receiving lithium therapy prospectively for 2 years; patients 
were mixed bipolar (n=48) and unipolar (n=5) subjects that 
had not previously been treated with lithium.28 Lithium sig-
nificantly increased serum PTH levels (progressively from 
2.8±1.2 pmol/L to 3.9±1.5 pmol/L after 2 years), while no 
changes in serum calcium levels were detected. The increase 
in PTH levels was evident after 1 month from the beginning 
of the treatment, although the difference became statistically 
significant only after 6 months.28
Prospective longitudinal studies seem to suggest that 
serum PTH levels do rise on lithium treatment, although 
the studies do diverge concerning calcium measurements: 
Christiansen et al found an increase in calcium from the first 
month, while Aronoff et al, Nielsen et al, and Mak et al did 
not detect any change in serum calcium levels.25–28 Longitu-
dinal studies also differ in identifying the time of occurrence 
of the increase in PTH levels: In the Nielsen et al study, 
PTH increased within the first week from lithium institution, 
while Christiansen et al found a significant increase in PTH 
levels after 1 month, and in the Mak et al study, an increase 
was evident after 1 month from beginning of the treatment, 
although the difference became statistically significant only 
after 6 months.26–28
Finally, when lithium therapy is stopped, both blood 
calcium and PTH normalize within several months. If hyper-
calcemia persists after withdrawal of lithium, decisions about 
surgery follow the same guidelines as those for patients with 
primary hyperparathyroidism.29
Hyperparathyroidism is associated with increased admis-
sions for nonfatal cardiovascular disease, renal failure, renal 
stones, fractures, hypertension, cancer, and diabetes; the 
investigation of long-term consequences of lithium on para-
thyroid function is then relevant for clinical practice.
The aim of the present retrospective longitudinal study was 
to compare serum PTH and calcium levels in lithium-exposed 
bipolar patients before and after lithium institution.
Material and methods
subjects
A retrospective, longitudinal, naturalistic study design was 
used. The data were retrieved from the database of the 
Anxiety and Mood Disorder Unit, Department of Neurosci-
ence of the University of Turin (Italy), examining patients 
referred between January 2010 and July 2014. Included in 
the study were patients (in- and outpatients) with a primary 
diagnosis of Diagnostic and Statistical Manual of Mental 
Disorders Version 4 (DSM-IV) Bipolar Disorder I or II30 
(made by psychiatrists with the Structured Clinical Interview 
for DSM-IV-TR Axis I Disorders [SCID-I/P]31). Inclusion 
criteria were: 1) at least 18 years of age; 2) patients had to 
have never been exposed to lithium before; 3) and had to have 
started lithium, with a lithium blood level checked at least 5 
days after lithium reached the target oral dose. The electronic 
medical files (for inpatients) and the medical charts (for 
outpatients) were reviewed for clinical data and for changes 
in PTH levels, and serum total and ionized calcium levels; 
thyroid stimulating hormone (TSH), triiodothyronine (T3) 
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and thyroxine (T4), creatinine, urea, sodium, and potassium 
levels were also examined. When possible, magnesium and 
phosphate levels were also retrieved. A baseline diagnosis 
of renal failure, serum creatinine value 1.5 mg/dL, use of 
diuretics or medications known to impair vitamin D metabo-
lism, and/or preexisting disorders of calcium homeostasis 
were considered exclusion criteria. The Ethics Committee 
of the San Giovanni Battista University Hospital approved 
the study design.
assessments and procedures
All bipolar subjects referred to our unit (inpatients or outpa-
tients) are examined at their first visit with a semistructured 
interview, with a format that covers the following areas: 
a) sociodemographic data; b) diagnoses (current and lifetime) 
provided by clinicians with at least 4 years of postgraduate 
clinical experience, by means of the SCID-I/P;32 c) clinical 
data (such as type of BD, age at onset of first-ever mood 
episode, and total number of episodes); d) the Young Mania 
Rating Scale (YMRS),33 17-item Hamilton Depression 
Rating Scale (HAM-D), 34 Hamilton Anxiety Rating Scale 
(HAM-A),35 and Clinical Global Impression Scale-Severity 
of Illness.36 Use of medications at the time of interview is also 
recorded; moreover, lifetime exposure to mood stabilizers 
is recorded by means of direct interview, family members’ 
interview (when available), and medical records review.
A blood draw for routine blood exam is performed at 
hospital admission for inpatients, as a part of the clinical 
management routine. For outpatients, patients are scheduled 
for a blood test within a week from the study visit. At the time 
when blood is drawn, patients have been fasting for the previ-
ous 10 hours. Blood exams include complete blood count, 
PTH, total and ionized calcium, TSH, T3 and T4, creatinine, 
urea, sodium and potassium, and lithium serum levels. For 
the purposes of the present study, we recorded these data as 
baseline data (before initiation of lithium treatment).
In addition, for most patients who are regularly followed at 
our unit as outpatients, we monitor PTH, calcium, TSH, crea-
tinine, urea, electrolytes, and plasma lithium levels every 3–6 
months (according to International Society for Bipolar Disorders 
[ISBD] clinical guidelines).37 For the purposes of the present 
study, we recorded the last available blood tests taken during 
follow-up; these data, taken when patients were on a stable 
maintenance lithium dose, were defined as the end point.
Exposure to lithium was calculated as mean lithium 
level (mmol/L) in the follow-up period for each patient; 
all lithium levels recorded in the hospital databases during 
these retrospective periods were used to compute the mean 
lithium level. Duration of lithium exposure in months was 
also computed for each patient.
statistical analysis
Primary outcome measures were changes in PTH levels, and 
total and ionized calcium, between baseline (off lithium or 
before lithium institution) and end of study (end of follow-up 
on lithium). The secondary outcome measures were changes 
in TSH, creatinine, urea, sodium, potassium, magnesium and 
phosphate levels between baseline and follow-up. Paired 
t-tests were used to analyze changes in primary and secondary 
outcome variables. Lastly, linear regressions were performed, 
with mean lithium level and duration of lithium exposure as 
the main independent variables and change in PTH levels as 
the dependent variable.
Results
Of approximately 500 charts screened, 34 bipolar patients 
had lithium instituted for the first time ever and had at least 
another blood test taken with serum PTH and calcium levels 
during follow-up; of these, three subjects were excluded 
because of hyperparathyroidism (PTH 65 pg/mL) at base-
line, due in all cases to 25OH-vitamin D levels 20 ng/mL. 
A total 31 patients constituted our sample. The mean duration 
of lithium treatment (mean length of follow-up) was 18.6±11.4 
months (range 6–48 months). The mean lithium oral dose at 
end of follow-up was 720.8±227.2 mg/day, and mean plasma 
lithium level during the follow-up period was 0.66±0.12 
mmol/L. Sociodemographic and clinical characteristics of 
patients included at baseline are reported in Table 1.
Changes in parameters related to calcium metabolism are 
reported in Table 2. A significant increase was only reported 
for PTH levels (mean increase of 13.55±14.20 pg/mL). Five 
(16.1%) patients developed hyperparathyroidism (PTH 
levels 65 pg/mL) during the follow-up; of these, one had 
25OH-vitamin D levels 20 ng/mL, and once vitamin D 
was supplemented, PTH levels returned within the normal 
range. The rate of lithium-associated hyperparathyroidism 
in our sample was then 12.9% (4/31 subjects). Of note, 
PTH levels increased without a parallel increase in calcium 
(total or ionized) levels (mean increase in total calcium was 
0.03±0.11 mmol/L; the mean change in ionized calcium 
was -0.01±0.1 mmol/L).
Table 3 shows changes in thyroid and renal function 
parameters during the 18.6 month follow-up period. No sta-
tistically significant changes were found in thyroid and renal 
function parameters except for an increase, from baseline to 
follow-up, in TSH levels. The proportion of patients with 
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clinical hypothyroidism (patients with replacement therapy 
or TSH 4.2 µIU/mL and free T3 2.6 pg/mL) increased 
also, from 3.2% to 12.9% at the end of follow-up. Body mass 
index (BMI) did not change during lithium treatment.
Linear regression analyses did not show an effect of either 
mean lithium level (analysis of variance [ANOVA]: F=0.194, 
P=0.663) or duration of lithium exposure (ANOVA: F=0.451, 
P=0.507) on changes in serum PTH levels.
Discussion
Our retrospective longitudinal study confirmed that main-
tenance lithium treatment is associated with a significant 
increase in serum PTH levels: The mean increase found 
in the present study was 13.5 pg/mL during an 18-month 
follow-up period. Long-term lithium treatment was also 
associated with hyperparathyroidism: A total 12.9% of bipo-
lar subjects never exposed to this compound before showed, 
during the follow-up, PTH levels 65 pg/mL. This rate of 
hyperparathyroidism is even higher than what we described 
in a previous study.17 Interestingly, neither total calcium nor 
ionized calcium levels increased during lithium treatment 
in our cohort. We have previously described an increase in 
PTH and ionized calcium levels in a group of 58 patients in 
continuous lithium treatment, in line with other literature 
data highlighting an association between hypercalcemia and 
lithium therapy.17 Magnesium and phosphate levels also did 
not change during follow-up.
Our results are in line with those of the previous longitudi-
nal studies performed to date. Serum PTH levels were found 
to rise during lithium treatment.26–28 Concerning calcium 
levels, the majority of the prospective studies did not detect 
any change in serum calcium levels, while only Christiansen 
et al found an increase in calcium.25–28 Longitudinal stud-
ies, then, do suggest that the effect of lithium on calcium 
homeostasis is primarily mediated through an increase in 
PTH levels; the lack of any significant change in the serum 
calcium level indicates that for any given level of calcium, the 
PTH concentration is higher during stable lithium therapy. 
Lithium-associated hyperparathyroidism, then, appears 
to be independent of calcium levels. In the present study, 
Table 1 sociodemographic and clinical characteristics of the 
included patients
Patients never exposed 
to lithium (N=31)
actual age (years), mean ± sD 48.4±15.2
sex (male), n (%) 12 (38.7)
educational level (years), mean ± sD 12.8±4.6
Marital status, n (%)
Married
Divorced
Never married
Widowed
17 (54.8)
2 (6.5)
11 (35.5)
1 (3.2)
currently working, n (%) 17 (54.8)
Bipolar disorder, n (%)
Type i
Type ii
19 (61.3)
12 (38.7)
age at onset (years), mean ± sD 27.6±8.9
Total number of episodes, mean ± sD 7.6±5.3
Duration of illness (years), mean ± sD 21.8±12.5
lithium mean dose (mg/day), mean ± sD  
(min–max)
720.8±227.2 (300–1200)
Blood lithium levels (mmol/l), mean ± sD 0.66±0.12
length of follow-up (months), mean ± sD  
(min–max)
18.6±11.4 (6–48)
BMi, mean ± sD 25.9±5.1
Abbreviations: BMi, body mass index; max, maximum; min, minimum.
Table 2 Serum PTH and calcium levels at first (basal) and last (end point) measurements
Baseline 
(off lithium)
Follow-up 
(on lithium)
Paired t-test
N=31 N=31 t P-values
PTh (pg/ml), mean ± sD
Normal range: 15–65 pg/ml
34.90±11.63 48.45±15.83 -5.313 0.001
hyperparathyroidism, n (%)* 0 (0) 5 (16.1) – –
Total calcium (mmol/l), mean ± sD
Normal range: 2.20–2.60 mmol/l
2.32±0.09 2.36±0.08 -1.571 0.127
hypercalcemia, n (%)** 0 (0) 0 (0) – –
ionized calcium (mmol/l), mean ± sD
Normal range: 1.10–1.32 mmol/l
1.13±0.10 1.12±0.07 0.420 0.677
hypercalcemia, n (%)† 1 (3.2) 0 (0) – –
Magnesium (mmol/l), mean ± sD
Normal range: 0.62–1.06 mmol/l
0.88±0.17 0.84±0.10 0.954 0.348
Phosphate (mmol/l), mean ± sD
Normal range: 0.81–1.45 mmol/l
1.04±0.22 1.01±0.12 0.684 0.499
Notes: *Defined as PTH 65 pg/mL. **Defined as total calcium 2.60 mmol/l. †Defined as ionized calcium 1.32 mmol/l.
Abbreviation: PTh, parathyroid hormone.
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calcium levels did not change over an 18-month follow-up 
period and hypercalcemia rates were 5%, consistent with 
recent studies using relatively stringent (and clinically use-
ful) definitions for clinical hypercalcemia.18,38,39 Our study, 
moreover, adds to previous findings demonstrating that, also, 
post-lithium phosphate levels do not differ from pre-lithium 
levels.26–28
It is still unclear whether lithium initiates the disease or 
uncovers an underlying state of hyperparathyroidism. Putative 
mediating mechanisms include the induction of parathyroid 
hyperplasia and/or adenomas;15,40 interference with the nega-
tive feedback loop for parathyroid hormone secretion, through 
altering the threshold of calcium-sensing receptors;15,41 and 
inhibition of glycogen synthase kinase 3b.42
Our results clearly show that lithium treatment may affect 
calcium metabolism, although the proportion of patients with 
overt hyperparathyroidism is low. What are the implica-
tions for clinical practice? Patients who developed lithium-
associated hyperparathyroidism, in our cohort, did not show 
any signs or symptoms, having total and ionized calcium 
levels within the normal ranges. Normocalcemic primary 
hyperparathyroidism is a well-documented nosographic 
entity and is related to reduced bone density.43 Lithium treat-
ment for bipolar disorder is usually lifelong; continuously 
elevated PTH levels, even with normal calcium levels, can 
thus lead to reduced bone mineral density, osteoporosis and 
increased fracture risk. Moreover, older patients and patients 
with comorbid renal disease may be especially vulnerable to 
developing symptomatic hypercalcemia and hyperparathy-
roidism requiring treatment.44 The consequences in term of 
reduced mobilization, disability, and health care costs have 
to be balanced against the cost of PTH measurements.
The question of whether clinicians should avoid lithium 
in patients with preexisting hypercalcemia/hyperparathyroid-
ism is an important one for future studies to ascertain. It is 
probably premature to state that this is the case at the current 
time. In the case of lithium use in patients with renal failure, 
for example, it is still advisable to continue lithium most of 
the time, when carefully weighing the pros and cons of this 
medication.45 It is possible that future studies will give us 
clinically meaningful indications about prescribing lithium 
in subjects at risk for hypercalcemia/hyperparathyroidism. 
As clinicians, however, we have to counterbalance the risks 
associated with the use of a specific drug (eg, lithium) versus 
benefits of its long-term use and risks associated with its 
discontinuation. For lithium, there is a clear demonstration 
that rapid discontinuation of its use is associated with affec-
tive relapses.11
This study has several limitations. First of all, there was 
no control group. Moreover, the size of the sample was small. 
However, the strength of our study is in the selection of a 
group of patients never exposed to lithium before, for which 
we could examine PTH and calcium levels (both total and 
ionized calcium) at baseline (before lithium institution) and at 
follow-up (on stable lithium treatment). The relatively long-
term follow-up (mean 18.6 months) is another strength of the 
present study; previous longitudinal studies followed patients 
for 2 months25 or 3 months,26 and only Mak et al had a longer 
follow-up (24 months).28 Our results need to be confirmed in 
greater samples prospectively followed up.
Table 3 Thyroid and renal function parameters at first (basal) and last (end point) measurements
Baseline
(off lithium)
Follow-up
(on lithium)
Paired t-test
N=31 N=31 t P-values
clinical hypothyroidism, n (%)* 1 (3.2) 4 (12.9) – –
Tsh (µiU/l), mean ± sD
Normal range: 0.27–4.2 µiU/ml
1.95±1.41 2.61±1.50 -2.040 0.050
creatinine (mg/dl), mean ± sD
Normal range: 0.5–1.5 mg/dl
0.79±0.16 0.82±0.17 -1.443 0.159
Urea (mg/dl), mean ± sD
Normal range: 10–50 mg/dl
29.84±8.43 27.06±7.9 2.002 0.054
sodium (mmol/l), mean ± sD
Normal range: 135–145 mmol/l
141.3±2.5 140.7±2.8 0.950 0.350
Potassium (mmol/l), mean ± sD
Normal range: 3.5–5.0 mmol/l
4.09±0.31 4.18±0.25 -1.485 0.148
BMi, mean ± sD 25.98±5.08 25.66±4.93 0.779 0.442
Psoriasis, n (%)** 0 (0) 1 (3.2) – –
Notes: *Patients with replacement therapy or Tsh 4.2 µiU/ml and FT3 2.6 pg/ml. **clinical diagnosis made by dermatologist.
Abbreviations: BMi, body max index; FT3, free triiodothyronine; Tsh, thyroid stimulating hormone.
Neuropsychiatric Disease and Treatment 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1790
albert et al
What remains to be further determined is a) which 
patients are more prone to develop lithium-associated altera-
tions in calcium homeostasis and b) whether longer expo-
sures to lithium (years) will end in hypercalcemia and then 
symptomatic hyperparathyroidism. In our study, we failed 
to show a relationship between the duration of exposure to 
lithium or the mean plasma level of lithium and PTH levels. 
We can conclude, then, that lithium exposes subjects at a 
higher risk of an increase in PTH levels and overt hyper-
parathyroidism but that we still don’t know which patients 
are particularly vulnerable.
Conclusion
In conclusion, our study shows that lithium does raise PTH 
levels without altering calcium levels. However, despite 
results of the studies pointing to an association between 
lithium treatment and hyperparathyroidism, serum calcium 
monitoring is not included in the most recent National Insti-
tute for Health and Care Excellence (NICE) and American 
Psychiatric l Association (APA) guidelines for the manage-
ment of patients with BD on long-term lithium therapy.1,2 
Only the ISBD recommends the addition of calcium (but not 
PTH levels) to the baseline battery of investigations when 
treatment with lithium is planned.9,37 Repeating serum cal-
cium at 6 months and then annually is also recommended.37 
As a consequence, serum calcium and PTH remain poorly 
monitored in patients on long-term lithium treatment in clini-
cal practice. Lally et al assessed the extent of screening for 
calcium dysfunction in a cohort of individuals on long term 
lithium therapy who were monitored by their general prac-
titioners over a 2-year period and found that 14.4% of 333 
patients did not have a serum calcium level measured over 
this period.38 The measurement of PTH was only performed 
in a third of patients with a raised calcium level (5.3% was 
the prevalence of hypercalcemia).
Clinicians should be aware of the efficacy of lithium 
in the prophylaxis of BD but also of the potential adverse 
effects associated with long-term lithium use, including 
hyperparathyroidism. The evaluation of serum PTH and 
calcium level should be added to baseline blood tests 
before lithium implementation and during long-term lithium 
maintenance.46 Moreover, it seems prudent to avoid lithium 
therapy in patients with preexisting hypercalcemia, although 
this remains to be further investigated. Routine screening 
evaluation of PTH levels has not been considered necessary 
until after abnormalities in calcium have been documented.47 
However, given the results of our study showing a more 
frequent finding of elevated PTH levels in comparison with 
serum calcium concentrations, we speculate that monitoring 
PTH rather than calcium level in lithium-treated patients 
should be advised. In fact, inappropriately high serum con-
centration of PTH sustains excessive renal calcium reabsorp-
tion, phosphaturia, and 1,25(OH)
2
D synthesis, as well as 
increased bone resorption.
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